CLLS · Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Market Cap
92.76M
52 Wk Range
$0.88 - $5.45
Previous Close
$0.98
Open
$0.99
Volume
52,628
Day Range
$0.90 - $1.00
Enterprise Value
50.68M
Cash
146.7M
Avg Qtr Burn
-16.18M
Insider Ownership
0.00%
Institutional Own.
13.42%
Qtr Updated
Sep 30th 2026
